Methods for the Diagnosis, Control and Prophylaxis of Inflammation and Mitigation of Inflammatory Conditions in Canines

• US 20130041024A1
• Filed: 05/05/2011
• Published: 02/14/2013
• Est. Priority Date: 05/12/2010
• Status: Active Grant

• Current Assignee: Hill's Pet Nutrition Incorporated (Colgate-Palmolive Company)
• Original Assignee: Hill's Pet Nutrition Incorporated (Colgate-Palmolive Company)
• Inventors: Frantz, Nolan Zebulon
• Granted Patent: US 10,564,169 B2
• Time in Patent Office: Days
• US Class Current: 514/458
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: G01N 2800/105 Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The invention relates to methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in canines, comprising measuring inflammatory biomarkers wherein elevated levels of the biomarkers in blood correlates to reduced inflammation and reduced levels in blood correlates to increase level in the tissues. The invention further provides a method to treat or control inflammation comprising administering a diet comprising increased levels of one or more of DHA, EPA, vitamin C, vitamin E, and/or L-carnitine.

Claims

1. A method of detecting an inflammatory condition in a canine, comprising measuring blood levels of one or more inflammatory biomarkers, wherein increased expression in blood is correlated with reduced inflammation in the tissue.

2. The method of claim 1 wherein the biomarker to be measured is selected from one or more of:

IL-6, ADAMTS-4, IFNG, HAS2, BGN, SOX-9, ADAMTS-5, MMP3, ACP5, IL1A, TNC, HAS3, COMP, IGF-1, GHR, Xaa-Pro Peptidase, RANKL, SMAD7, PGE2, TLR9, PLOD1, and SCL2A9.

3. The method of claim 1 or 2 further comprising measuring blood levels of ANXA1 wherein decreased levels of ANXA1 levels correlates with reduced inflammation in the tissue.

4. The method of claim 1, 2, or 3 wherein the inflammatory condition is treated or controlled by administering a diet comprising increased levels of one or more of DHA, EPA, vitamin C, vitamin E, and/or L-carnitine relative to a standard diet.

5. The method of claim 4 wherein the diet is administered for a period of at least two weeks.

6. The method of claim 4 or 5 wherein the diet comprises DHA+EPA in an amount of 0.25-5% on a dry weight basis.

7. The method of claim 4 wherein the diet comprises on a dry weight basis:

DHA+EPA;

0.5-2.5%

Vitamin C;

75-1000 mg/kg

Vitamin E;

250-1000 mg/kg

L-carnitine;

100-1000 mg/kg

8. The method of claim 4 wherein the diet has approximately the nutritional composition of the test diet of Example 1.

9. The method of any of the foregoing claims wherein the condition to be controlled or treated is osteoarthritis.